These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 167445)
21. [Serum and urine lysozyme activity in various blood disorders and hypopotassemia in leukemia]. Shimizu M; Takabayashi Y; Asai I; Nishina T; Niwa S Rinsho Ketsueki; 1972 Aug; 13(4):549-59. PubMed ID: 4509361 [No Abstract] [Full Text] [Related]
22. Serum muramidase in haematological disorders: diagnostic value in neoplastic states. Firkin FC Aust N Z J Med; 1972 Feb; 2(1):28-33. PubMed ID: 4502715 [No Abstract] [Full Text] [Related]
23. [Evaluation of a one step sandwich enzymeimmunoassay for serum erythropoietin--serum erythropoietin values in polycythemia vera and related hematological disorders]. Sawabe Y; Iida S; Tabata Y; Yonemitsu H Rinsho Byori; 1993 Jan; 41(1):75-82. PubMed ID: 8355412 [TBL] [Abstract][Full Text] [Related]
24. Serum and urinary lysozyme in leukaemia and polycythaemia vera. Malmquist J Scand J Haematol; 1972; 9(3):258-66. PubMed ID: 4507075 [No Abstract] [Full Text] [Related]
25. [Prognostic usefulness of lysozyme in acute myelomonocytic leukemias]. Liso V; Laricchia R Minerva Med; 1983 Jun; 74(27):1595-600. PubMed ID: 6574344 [TBL] [Abstract][Full Text] [Related]
26. A study on the clinical significance of serum and urinary muramidase activity in leukemics. Nagase H Nagoya J Med Sci; 1971 Jun; 34(1):13-26. PubMed ID: 5286505 [No Abstract] [Full Text] [Related]
27. Serum phospholipase A in hematological diseases. Hiefinger RT; Guder WG; Hoffmann GE Klin Wochenschr; 1989 Feb; 67(3):222-4. PubMed ID: 2927059 [TBL] [Abstract][Full Text] [Related]
28. Physician Education: Myelodysplastic Syndrome. Yoshida Y Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004 [TBL] [Abstract][Full Text] [Related]
29. [Jamshidi biopsy in clinical hematology. Method, indications and results of over 1,000 completed biopsies with special reference to chronic myeloproliferative diseases]. Seewann HL Wien Med Wochenschr Suppl; 1986; 100():1-24. PubMed ID: 3471009 [TBL] [Abstract][Full Text] [Related]
30. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088 [TBL] [Abstract][Full Text] [Related]
31. [Transcobalamines and lysozyme in leukemia and in myeloproliferative syndromes]. Zittoun J; Jarret J; Zittoun R; Sultan C Nouv Rev Fr Hematol; 1974; 14(2):324-30. PubMed ID: 4277305 [No Abstract] [Full Text] [Related]
32. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders]. Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237 [TBL] [Abstract][Full Text] [Related]
33. Serum lysozyme activity in some myeloproliferative diseases. Merkiel K; Prokopowicz J; Bielawiec M; Kiersnowska B Haematologia (Budap); 1977; 11(1-2):111-4. PubMed ID: 276510 [TBL] [Abstract][Full Text] [Related]